Adolfo Garcı́a-Ocaña

This study develops CYP8B1-specific inhibitors that alter bile acid composition, remodel gut microbiota, and improve metabolic disease in a mouse model.

This study investigates the role of UPP1 in β-cell function and shows that UPP1 deficiency impairs uridine-potentiated GSIS and MAPK activation in mice and humans.

This study shows that harmine plus exendin-4, when combined with anti-CD3 therapy, promotes beta-cell recovery and reduces immunogenicity, leading to remission of recent-onset type 1 diabetes.

This paper shows harmine, a DYRK1A inhibitor, selectively promotes human beta cell differentiation and function via PKA activation, distinct from other DYRK1A inhibitors.

This study shows that nutrient excess remodels pancreatic islet innervation through Schwann cells, impairing glycemic control, and demonstrates that neuromodulation can improve outcomes.

This study shows LGR4 maintains beta-cell health by suppressing RANK, with effects observed in both in vitro and mouse models under stress and aging.

This study shows that acute inhibition of iron-sulfur cluster biosynthesis in mice leads to metabolic inflexibility, reduced adiposity, and glucose dyshomeostasis, with effects mitigated in aged mice.

This study identifies harmine, 2-2c, and 5-IT as DYRK1A inhibitors that enhance both beta cell proliferation and differentiation, while others fail to induce differentiation.

This study shows that NRF2 dysregulation in mice impairs beta-cell proliferation and mass expansion during pregnancy, leading to gestational diabetes.